Archives
-
Chlorpromazine HCl: From Dopamine to Cell Entry
2026-09-22
Chlorpromazine HCl is more than a conventional dopamine receptor antagonist. This thought-leadership article connects its established neuropharmacology with emerging use as a probe of clathrin-mediated endocytosis and macropinocytosis in Spiroplasma eriocheiris infection models, while defining the controls and limitations needed for translational interpretation.
-
Angiotensin Peptides Enhance SARS-CoV-2 Spike Binding
2026-09-22
The 2025 reference study identifies a previously underappreciated structure–activity relationship in which naturally occurring angiotensin peptides increase SARS-CoV-2 spike protein binding to AXL, with angiotensin IV producing the strongest reported effect. Its deletion and residue-modification experiments connect peptide length and tyrosine chemistry to receptor-specific binding changes, while also defining important limits for interpreting these results beyond biochemical assays.
-
ML-7 hydrochloride in Cardiac I/R Workflows
2026-09-21
Learn how to use ML-7 hydrochloride as a mechanistic probe of MLCK signaling in cardiomyocyte, ischemia/reperfusion, and endothelial barrier assays. The workflow pairs pathway inhibition with annexin-V, phosphorylation, contractility, and tight-junction readouts so researchers can distinguish altered signaling from nonspecific cell injury.
-
RIPA Lysis Buffer Strong: Practical Workflow Guide
2026-09-21
RIPA Lysis Buffer (Strong, without inhibitors) supports detergent-intensive protein extraction from cultured animal cells and tissues for Western blotting, immunoprecipitation, ELISA, and selected kinase assays. Because it contains no protease or phosphatase inhibitors, it should be supplemented and processed promptly when protein modification or degradation is a concern; its strong detergent composition may require validation for native-complex or enzyme activity workflows.
-
CRISPR DNA Repair Pathway Choice by Drug Repurposing
2026-09-20
This study presents a large drug-repurposing screen that links clinically used compounds to distinct DNA double-strand break repair outcomes in human induced pluripotent stem cells. Its findings identify candidate modulators of NHEJ, MMEJ, and HDR, while also revealing ESR2-associated effects and potential synthetic-lethality strategies relevant to genome editing and cancer research.
-
BMP4-GPX4 Protects RGCs in NMDA Glaucoma Models
2026-09-19
The reference study identifies a BMP4–GPX4 pathway that links ferroptosis control with retinal ganglion cell survival and retinal stem cell differentiation in an NMDA-induced glaucoma model. Its findings support a mechanistic framework for improving transplantation outcomes, while also highlighting the limits of extrapolating an excitotoxic mouse model to chronic human glaucoma.
-
PPARγ, Macrophage Polarization, and DSS Colitis
2026-09-18
The reference study links PPARγ activation to improved DSS-induced colitis through coordinated changes in macrophage polarization and STAT-1/STAT-6 signaling. Its combined cell and mouse models provide a mechanistic framework for interpreting intestinal barrier repair, while also defining important limits for extrapolation to other PPARγ-associated disease areas.
-
ISR and Accelerated Forgetting in Epilepsy
2026-09-18
A 2025 Molecular Neurobiology study identifies integrated stress response activation as a molecular correlate of both natural forgetting and seizure-associated accelerated forgetting in mice. Its retention-interval experiments show that repeated ISRIB treatment can preserve established recognition memories, while a single administration does not alter retrieval, offering a mechanistic framework for studying maladaptive memory loss.
-
Mitoxantrone Assays: Workflow, Resistance & Optimization
2026-09-17
Build more informative Mitoxantrone experiments by separating topoisomerase II activity, apoptosis, intracellular exposure, and ABCG2-mediated resistance. This workflow also shows how to translate the marein–ABCG2 findings into practical combination and transporter assays without confusing chemosensitization with direct cytotoxicity.
-
Bufalin–STK33 Targeting in Triple-Negative Breast Cancer
2026-09-17
The 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct binding and degradation target of Bufalin in triple-negative breast cancer. By combining target discovery, binding validation, genetic perturbation, animal models, and patient-derived organoids, the work connects Bufalin exposure to disruption of the STK33–HSP90 complex and suppression of tumor-cell proliferation.
-
Recombinant Mouse SHH: Assay Design for Patterning
2026-09-16
Recombinant Mouse Sonic Hedgehog enables controlled studies of morphogen activity, from alkaline phosphatase induction to comparative genital-tubercle development. This article translates recent Shh evidence into practical assay-design decisions for developmental biology and congenital malformation research.
-
Berberrubine and the Vitamin K Cycle in Thrombosis
2026-09-16
The reference study integrates mouse thrombosis pharmacology, non-targeted metabolomics, and molecular docking to connect berberrubine with the vitamin K catalytic cycle. Its most important finding is a separation between prolonged prothrombin time and the absence of increased bleeding time, offering a mechanistic basis for further evaluation of this natural-product metabolite as an antithrombotic lead.
-
Tricine-SDS-PAGE Gel Preparation Kit Protocol
2026-09-15
The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit is designed for higher-resolution protein electrophoresis and peptide separation in the low-molecular-weight range, including targets from 1 to 10 kDa. It is intended for research workflows, not diagnostic or medical use, and should be validated with the laboratory’s own samples, markers, and running conditions.
-
Proteoform-Specific Drug Interactions in Native Membranes
2026-09-15
The reference study establishes a native mass spectrometry workflow for connecting membrane-protein post-translational modifications with ligand binding and complex assembly. Using retinal rod disc membranes, it resolves rhodopsin and G-protein proteoforms and reveals differential off-target recognition of PDE6 by sildenafil and vardenafil, offering a more precise framework for drug selectivity studies.
-
Cabazitaxel (XRP6258): Workflow and QC Guide
2026-09-14
Cabazitaxel (XRP6258, SKU B2157) provides a practical research option for antiproliferative assays involving taxane-resistant or P-glycoprotein-expressing cancer cell lines. It is suitable for DMSO- or ethanol-based workflows, but not for direct aqueous preparation or long-term storage of solutions.